bmp

Dorsomorphin (BML-275) is an AMPK inhibitor (Ki=109 nM) that is selective and ATP-competitive. Dorsomorphin inhibits the BMP type I receptors ALK2, ALK3, and ALK6. Dorsomorphin induces autophagy, and possesses antitumor activity.

LDN-212854 (BMP Inhibitor III), a novel BMP inhibitor, exhibits greater selectivity for BMP versus the TGF-β type I receptors; possesses differences towards ALK2(IC50=1.3 nM) versus ALK1/3 compared to other inhibitors.

Dorsomorphin dihydrochloride (BML-275 2HCl) is a potent, selective and ATP-competitive AMPK inhibitor (Ki: 109 nM) and does not exhibit significant activity on structurally related kinases.

BMP signaling agonist sb4 (SB 4) is an agonist of benzoxazole bone morphogenetic protein (BMP) signaling (EC50 :74 nM)

BMP-22 is an inhibitor of autotaxin (IC50 = 170 nM). It is selective for autotaxin over the phosphodiesterases NPP6 and NPP7 at 10 μM. BMP-22 (0.1-1,000 nM) inhibits autotaxin-mediated production of lysophosphatidic acid (LPA) from lysophosphatidylcholine in vitro in a concentration-dependent manner. It inhibits LPC-dependent MM1 cell invasion of a human umbilical vein endothelial cell (HUVEC) monolayer. BMP-22 (0.5 mg/kg per day) decreases the number of lung metastatic foci in a B16/F10 syngeneic mouse melanoma model of lung metastasis.

BMP Agonist 1 (compound 2 b) is a small-molecule stimulator of bone morphogenic protein (BMP) signaling, crucial for the differentiation of C2C12 cells. It acts by inhibiting GSK3β and enhancing β-catenin signaling, thereby synergistically modulating Id2 and Id3 expression. This compound is employed in skeletal disease and defect research [1].

BMP agonist 2 has up-regulated bone morphogenetic protein BMP-2 expression activity in vivo and anti-osteoporosis effects, and also has ameliorated the symptoms of osteoporosis in SAMP6 mice.BMP agonist 2 is an osteoinductive cytokine that promotes the production of bone tissue, and can be used in the study of senile osteoporosis (SOP).

18:1 Hemi BMP (S,R) is a reagent used in biochemical reactions.

BMP-4, a heparin-binding peptide, exhibits anti-inflammatory and anti-chondrogenic properties. In murine chondrocytes and macrophages, it effectively mitigates inflammation and alleviates symptoms of various arthritides by dose-dependently suppressing the expression of inflammatory proteins such as iNOS, COX2, IFN, and IL6 through modulation of the iNOS-IFN-IL6 signaling pathway.

TBMP (butylated hydroxyanisole) is the viral envelope protein hemagglutinin (HA)-mediated entry novel inhibitor.

BMP2-derived peptide, encompassing amino acids 73 to 92 of BMP-2, induces osteogenic differentiation in bone marrow stromal cells (BMSCs) and augments bone regeneration [1].

BMPS, a non-cleavable ADC linker, is utilized in the synthesis of antibody-drug conjugates (ADCs).

BBMP is an inhibitor of mitochondrial permeability transition pore.

BMPSP is a fluorescent DNA groove binding probe.

BMPR2-IN-1 (Compound 8a), is a potent inhibitor of BMPR2, exhibiting an IC50 value of 506 nM and a Kd of 83.5 nM. It is utilized in the study of various diseases including pulmonary arterial hypertension, Alzheimer's disease, and cancer [1].

BmP02, a compound isolated from Chinese scorpion (Buthus martensi Karsch) venom, acts as a selective Kv1.3 channel blocker and a highly-selective Kv4.2 modulator. It delays Kv4.2 inactivation in HEK293T cells, exhibiting an EC50 of approximately 850 nM, and inhibits the transient outward potassium currents (Ito) in ventricular muscle cells [1] [2].

TBMP (Standard) is the standard substance of TBMP, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. TBMP (butylated hydroxyanisole) is the viral envelope protein hemagglutinin (HA)-mediated entry novel inhibitor.

[Bmpip][NTf2] is composed of the 1-butyl-1-methylimidazolium cation and the bis(trifluoromethylsulfonyl)imide anion.

LDN193189 (LDN-193189) (DM 3189) is a selective BMP signaling inhibitor, inhibiting the transcriptional activity of ALK2 and ALK3 (IC50s: 0.8 0.8 5.3 16.7 nM for ALK1 2 3 6).

DMH-1 is a potent and selective Bone Morphogenetic Protein (BMP) inhibitor.

SY-LB-57 is a highly effective agonist of bone morphogenetic protein (BMP) receptor signaling, suitable for studies of conditions such as bone fractures and pulmonary arterial hypertension [1].

BMT-124110 is a selective AAK1 inhibitor (IC50: 0.9 nM) with antinociceptive activity. BMT-090605 inhibited BMP-2 induced protein kinase BIKE with IC50 of 17 nM. BMT-090605 inhibits cyclin G-associated kinase GAK with an IC50 of 99 nM.

BMT-124110 Formate is a selective AAK1 inhibitor (IC50: 0.9 nM) with anti-injury sensory activity.BMT-124110 Formate inhibits the BMP-2-inducible protein kinase BIKE with an IC50: 17 nM.BMT-124110 Formate inhibits the cell-cycle protein G-related BMT-124110 Formate inhibits the cell cycle protein G-associated kinase GAK with an IC50:99 nM.

LP-922761 is a potent, selective, and orally active AAK1 inhibitor with inhibitory effects on BMP-2 induced protein kinase (BIKE).